Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 240

1.

[Clinical features and prognosis of patients with primary light chain deposition disease].

Wang JN, Feng J, Cao XX, Duan MH, Zhang L, Zhou DB, Li J.

Zhonghua Xue Ye Xue Za Zhi. 2017 Mar 14;38(3):253-256. doi: 10.3760/cma.j.issn.0253-2727.2017.03.017. Chinese. No abstract available.

PMID:
28395454
2.

Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.

Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, Jo Kamimoto J, Hoque S, Radhakrishnan M, Matin A, Davis C, Grazziutti M, Thanendrarajan S, van Rhee F, Zangari M, Davies F, Morgan G, Epstein J, Barlogie B, Schinke C.

Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24756. [Epub ahead of print]

PMID:
28383130
3.

[Light-chain deposition disease is a hematologic problem].

Rekhtina IG, Mendeleeva LP, Biryukova LS.

Ter Arkh. 2017;89(1):38-43. Russian.

PMID:
28252625
4.

Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male.

Adamu B, Al-Ghamdi M, Ahmad M, Alsaad KO.

Case Rep Nephrol. 2016;2016:7485695. doi: 10.1155/2016/7485695. Epub 2016 Dec 19.

5.

Light Chain Deposition Disease Diagnosed with Laser Micro-dissection, Liquid Chromatography, and Tandem Mass Spectrometry of Nodular Glomerular Lesions.

Kasagi T, Nobata H, Suzuki K, Miura N, Banno S, Takami A, Yamashita T, Ando Y, Imai H.

Intern Med. 2017;56(1):61-66. doi: 10.2169/internalmedicine.56.7275. Epub 2017 Jan 1.

6.

Treatment of idiopathic light chain deposition disease: complete remission with bortezomib and dexamethasone.

Souto Filho JT, Monteiro JM, Andrade IB.

J Bras Nefrol. 2016 Dec;38(4):450-454. doi: 10.5935/0101-2800.20160071. Portuguese, English.

7.

Bortezomib Based Chemotherapy for Light Chain Deposition Disease.

Kandakumar V, Nagalapuram V, Menon S.

J Assoc Physicians India. 2016 Aug;64(8):97-98.

PMID:
27762125
8.

Intracystic hemorrhage in a patient with pulmonary cystic disorder related to light-chain deposition disease.

Gorospe Sarasúa L, Pacios-Blanco RE, Arrieta P, Chinea-Rodríguez A.

Arch Bronconeumol. 2017 May;53(5):285-287. doi: 10.1016/j.arbres.2016.08.008. Epub 2016 Oct 15. English, Spanish. No abstract available.

9.

Five Sequential Evaluations of Renal Histology in a Patient with Light Chain Deposition Disease.

Ueno T, Kikuchi K, Hazue R, Mise K, Sumida K, Hayami N, Suwabe T, Hoshino J, Sawa N, Arizono K, Hara S, Takaichi K, Fujii T, Ohashi K, Ubara Y.

Intern Med. 2016;55(20):2993-2999. Epub 2016 Oct 15.

10.

A case of light chain deposition disease in kidney in a known case of multiple myeloma.

Kanwar A, Mendonca S.

J Assoc Physicians India. 2016 Jan;64(1):126. No abstract available.

PMID:
27728501
11.

Unusual case of light chain deposition disease kappa restricted in a case of multiple myeloma.

Mendonca S, Choudhury A.

J Assoc Physicians India. 2016 Jan;64(1):123. No abstract available.

PMID:
27728483
12.

Unusual Presentation of Light Chain Deposition Disease: A Case Report.

Arora D, Uppal M, Amitabh V, Agrawal U.

J Clin Diagn Res. 2016 May;10(5):ED08-9. doi: 10.7860/JCDR/2016/18358.7762. Epub 2016 May 1.

13.

Spontaneous splenic rupture in a patient with light-chain deposition disease undergoing autologous peripheral blood stem cell transplantation.

Haji S, Kiyasu J, Tachikawa Y, Toyonaga J, Ikeda M, Tsuda M, Tsukamoto Y, Kozuru M, Yufu Y.

Rinsho Ketsueki. 2016 Jun;57(6):754-9. doi: 10.11406/rinketsu.57.754. Review.

PMID:
27384856
14.

siRNA targeting the κ light chain constant region: preclinical testing of an approach to nonfibrillar and fibrillar light chain deposition diseases.

Ma X, Zhou P, Wong SW, Warner M, Chaulagain C, Comenzo RL.

Gene Ther. 2016 Oct;23(10):727-733. doi: 10.1038/gt.2016.50. Epub 2016 Jun 20.

PMID:
27383253
15.

OCULAR MANIFESTATIONS OF MONOCLONAL IMMUNOGLOBULIN LIGHT CHAIN DEPOSITION DISEASE.

Dhrami-Gavazi E, Freund KB, Lee W, Cohen BZ, Seshan SV, Yannuzzi LA.

Retin Cases Brief Rep. 2016 Jun 16. [Epub ahead of print]

PMID:
27315323
16.

Nodular pulmonary light chain deposition disease.

Yee M, Delahunt B, Russell PA.

Pathology. 2016 Aug;48(5):515-8. doi: 10.1016/j.pathol.2016.04.012. Epub 2016 Jun 13. No abstract available.

PMID:
27306574
17.

Surgical Management of Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Associated With Light-Chain Deposition Disease.

Muñoz-Largacha JA, O'Hara CJ, Sloan JM, Fernando HC, Litle VR.

Ann Thorac Surg. 2016 Jun;101(6):e207-10. doi: 10.1016/j.athoracsur.2015.10.089.

PMID:
27211983
18.

Light Chain Deposition Disease in an Older Adult Patient Successfully Treated with Long-term Administration of Bortezomib, Melphalan and Prednisone.

Hiyamuta H, Yamada S, Matsukuma Y, Tsuchimoto A, Nakano T, Taniguchi M, Masutani K, Yoshimoto G, Muta T, Akashi K, Kitazono T, Tsuruya K.

Intern Med. 2016;55(10):1319-25. doi: 10.2169/internalmedicine.55.5752. Epub 2016 May 15.

19.

Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach.

Sivaraj D, Green MM, Ciftci AM, Zahid MF, Johns AA, Ross M, Gasparetto C.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e95-e100. doi: 10.1016/j.clml.2016.03.002. Epub 2016 Mar 29. Review. No abstract available.

PMID:
27101986
20.

Clinicopathological characteristics and outcomes of light chain deposition disease: an analysis of 48 patients in a single Chinese center.

Li XM, Rui HC, Liang DD, Xu F, Liang SS, Zhu XD, Huang XH, Liu ZH, Zeng CH.

Ann Hematol. 2016 May;95(6):901-9. doi: 10.1007/s00277-016-2659-1. Epub 2016 Apr 8.

PMID:
27056200

Supplemental Content

Loading ...
Support Center